HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

ghted that marketing authorisation for VELCADE has been granted, as it is the first major advance for patients with multiple myeloma in more than a decade, and marks the company's commitment to Oncology." said Ken Watters, European Medical Director, Ortho Biotech.

"The approval of VELCADE today brings renewed hope to thousands of European multiple myeloma patients and their families" said Eric Low, Executive Director, International Myeloma Foundation (UK). "The multiple myeloma advocacy community has campaigned tirelessly over the years for cutting edge treatments such as VELCADE to be made available to patients, this is a very proud day", he continued.

The findings of a pre-specified interim analysis from an ongoing phase III trial which compared VELCADE to dexamethasone in refractory multiple myeloma patients found a statistically significant improvement in time to disease progression the primary endpoint of the trial in patients receiving VELCADE compared to patients receiving high-dose dexamethasone. Patients in the control arm of the trial were given the opportunity to switch to VELCADE as soon as possible based on an interim analysis that found a statistically significant improvement in TTP in patients receiving VELCADE compared to patients receiving dexamethasone.

VELCADE has a generally predictable, manageable safety profile (with appropriate monitoring and if necessary, dose modification). VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. There are approximately 50 ongoing clinical trials (in Europe and the US) investigating the potential of VELCADE in all stages of multiple myeloma and other cancers.

A single licence has been granted to market VELCADE in the 15 member states of the EU, plus Norway and Iceland. In addition it will be available in the 10 accession countries.

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Ph
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... ... 2017 , ... An intensive search of the medical literature has revealed no ... PhD. He says investigating this possibility, is important because Miami-Dade in 2016 ... infections with HIV. , His findings appear on Analizir.com. . Dr. ...
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic Imaging, LLC, an ... and operational excellence in oncology clinical trials, proudly announces today that it has ... non-small cell lung cancer and small cell lung cancer. , Throughout this trial, ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... services to regional families and business owners, is joining the Teen Recovery Solutions ... in the area. , A growing number of Oklahoma teens and adolescents face ...
(Date:3/22/2017)... ... 22, 2017 , ... College basketball surges to its peak during the March ... that is, recruiting people to be foster parents. Through a televised spot, Coach Self ... foster care due to abuse, neglect and other family challenges. People who respond to ...
(Date:3/22/2017)... ... 2017 , ... Nearly a decade after it was first recommended that men ... screening continues to stir controversy. The US Preventative Services Task Force (USPSTF) issued a ... benefits. Now, news from a study published in JAMA Oncology suggests that ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017  Ablation is the ... a wide range of purposes, from cancerous or ... conducting cardiac tissue in atrial fibrillation and others. ... pushing the researchers to innovate and improvise existing ... The ablation device global market is expected to ...
(Date:3/22/2017)... 2017  Applied BioMath ( www.appliedbiomath.com ), the ... and development, today announced the latest line-up of ... is a day full of presentations, posters, and ... community. The focus is to learn about how ... drug research and development. The event ...
(Date:3/22/2017)... A new independent study demonstrates that ... ultraviolet-C (UV-C) disinfection solution of choice for combating ... Published in the March issue of the ... peer-reviewed study of UV-C disinfection systems detailed the ... and Rochester General Hospital. According to the study, ...
Breaking Medicine Technology:
Cached News: